Please check your internet connection and try again.
# L-Ornithine L-Aspartate (LOLA)
## Overview
L-ornithine L-aspartate (LOLA) is a stable salt of two amino acids that serves as a substrate for the urea cycle and glutamine synthesis. It facilitates ammonia detoxification by promoting the conversion of ammonia to urea and glutamine, primarily in the liver and muscle tissue.
## Primary Indications
* Management of hyperammonemia in liver disease.
* Treatment of latent and overt hepatic encephalopathy (HE).
## Adult Dosing
* **Oral (Granules):** 3g to 6g administered three times daily (total 9gā18g/day) with meals.
* **Intravenous (IV) Infusion:** 20g to 40g per 24 hours, administered via continuous infusion (e.g., in 500mL of compatible IV fluid). Do not exceed 5g per hour.
* *Note: Dosing varies by regional protocol and severity of encephalopathy; follow facility-specific clinical guidelines.*
## Pediatric Dosing
Safety and efficacy in pediatric populations are not well established. Use is generally restricted to specialized hepatology settings and requires weight-based titration at the discretion of a pediatric specialist.
## Dose Adjustments
* **Renal Impairment:** Use with caution. In cases of severe renal impairment (creatinine >3 mg/dL), LOLA may accumulate. Dose reduction or avoidance is suggested.
* **Hepatic Impairment:** No dose reduction is typically required for liver disease, as it is intended to support hepatic function; however, monitor for fluid overload during IV administration.
## Contraindications
* Chronic renal failure (Creatinine levels >3 mg/dL).
* Hypersensitivity to L-ornithine or L-aspartate.
* Severe hepatic failure with anuria.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain.
* **Less Common:** Arthralgia, limb pain, fatigue.
* **Rare:** Injection site reactions (if infused too rapidly).
## Key Drug Interactions
* No major high-risk drug-drug interactions are documented; however, avoid mixing with other drugs in the same IV line to prevent potential precipitation or incompatibility.
## Monitoring
* **Clinical Status:** Monitor mental status, cognitive function, and symptoms of encephalopathy.
* **Laboratory:** Serum ammonia levels (though correlation with clinical state may be poor) and renal function (BUN/Creatinine).
* **Fluid Status:** Monitor for edema or signs of fluid overload during IV administration.
## Clinical Pearls
* LOLA is considered an adjunctive treatment and does not replace the cornerstone therapies of HE, specifically lactulose and rifaximin.
* IV administration must be slow to prevent infusion-related nausea and vomiting.
* Evidence supporting long-term efficacy remains heterogeneous; practitioners should emphasize the correction of precipitating factors (e.g., GI bleed, infection, electrolyte imbalance) alongside LOLA therapy.
***
**Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and clinical protocols can vary significantly by region and institution. Always verify specific dosing, safety data, and contraindications by consulting the official product monograph or current local pharmacy prescribing guidelines before administration.
